


Table 1. Demographic characteristics of the study population	
Age (years)	65.0 ± 1.5
Gender (male/female)	10/10
Education (years)	12.0 ± 1.0
Marital status (married/divorced/widowed)	10/0/0
Occupation (retired/employed)	10/0
Income (USD/month)	1,200.0 ± 100.0
Health status (good/poor)	10/0
Smoking status (smoker/non-smoker)	0/10
Alcohol consumption (yes/no)	0/10
Comorbidities (hypertension/diabetes/cholesterol)	5/2/3
Medication (yes/no)	10/0
Family size (number of children)	2.0 ± 1.0
Living arrangement (alone/together)	10/0
Religious affiliation (Christian/Jewish/Muslim)	10/0/0
Language spoken at home (Hebrew/Arabic)	10/0
Country of origin (Israel/Abroad)	10/0
Duration of residence in Israel (years)	20.0 ± 5.0
Previous psychiatric history (yes/no)	0/10
Current psychiatric treatment (yes/no)	0/10
Family psychiatric history (yes/no)	0/10
Stressful life events (yes/no)	0/10
Social support (high/low)	10/0
Life satisfaction (high/low)	10/0
Overall health perception (good/poor)	10/0

30. A compound of formula I




wherein:

- R₂ and R₄ are, independently of each other, a hydrogen atom or a methyl group;

- R₃ is a hydrogen atom or a hydroxyl group;

- X is a CO, CHOH or CH₂ group; and

- R_1 is:



wherein

- for meta derivatives:

A, C, D, and E each is a hydrogen atom, and B is:

- a halogen,

- a monoalkylamino or dialkylamino group,

- an ether group,
- a thioether group,
- a C₁ to C₃ alkyl group, or
- a trihalogenomethyl group,

- for para derivatives:

A, B, D, and E each is a hydrogen atom, and C is:

- a halogen,
- an NR₁R₂ group, wherein R₁ and R₂ each is, independently of one

another, a group selected from

- hydrogen,
- a straight-chain or branched C₁ to C₄ alkyl group wherein
- if one of the substituents R₁ or R₂ is a methyl group, the other necessarily is an ethyl group,
- an alkyl-cycloalkylmethyl group, wherein said cycloalkyl
- is a C₃ to C₄ cycloalkyl,
- a substituted or unsubstituted C₃ to C₄ cycloalkyl group,
- a straight-chain or branched C₂ to C₄ alkenyl group,

wherein if one of the substituents R₁ to R₂ is an alkenyl group, the other is not a methyl group and is not a C₃ to C₆ cycloalkyl group,

- a substituted or unsubstituted N-pyrrolidinyl group,
- an ether group,
- a thioether group,
- an acyl or alkoxycarbonyl group,

- a C₁ to C₆ alkyl group, wherein said alkyl group is straight-chain

or branched,

- an alkythiomethyl group,

- an aryl group,

or

- a trihalogenomethyl group, and

- for meta-para disubstituted derivatives:

A, D, and E each is a hydrogen atom, and B is:

- a halogen,

- a monoalkylamino or dialkylamino group,

- an ether group

- a thioether group,

- a C₁ to C₃ alkyl group, and

C is:

- a halogen,

- an amino, monoalkylamino or dialkylamino group, with the

proviso that B is not a bromine atom, a chlorine atom, or a substituted or unsubstituted allyl group,

- an ether group,

- a thioether group,

- a C₁ to C₆ alkyl group, or

- a trihalogenomethyl group, and

- for ortho-para disubstituted derivatives:

B, E, and D each is a hydrogen atom, and A and C each is a methyl group.

31. (New) A compound according to claim 30, wherein said compound is at

least one of:

4ζ-methylthio-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-methyl-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-methoxy-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-methoxycarbonyl-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-chloro-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-bromo-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-iodo-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-trifluoromethyl-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-tert-butyl-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-isopropyl-de(4ζ-dimethylamino)pristinamycin I_λ;
4ε-methylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-ethylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-diethylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-allylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
4ζ-diallylamino-de(4ζ-dimethylamino)pristinamycin I_λ; and
4ζ-allylethylamino-de(4ζ-dimethylamino)pristinamycin I_λ.

32. A compound according to claim 30, wherein said compound is at least one

of:

4ζ-ethylpropylamino-de(4ζ-dimethylamino)pristinamycin I_λ;

4ζ-ethylisopropylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-ethylmethylcyclopropylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-(1pyrrolidiny)-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-trifluoromethoxy-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-allyloxy-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-ethoxy-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-ethylthio-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-methylthiomethyl-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-(2-chloroethoxy)-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-acetyl-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ζ-ethyl-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ε-dimethylamino-de(4ζ-dimethylamino)pristinamycin I_λ;
 4ε-methylthio-de(4ζ-dimethylamino)pristinamycin I_λ; and
 4ε-ethoxy-de(4ζ-dimethylamino)pristinamycin I_λ.

33. A compound according to claim 30, wherein said compound is at least one

of:

4ζ-methylthio-de(4ζ-dimethylamino)pristinamycin I_H;
 5γ-hydroxy-4ζ-methylthio-de(4ζ-dimethylamino)pristinamycin I_H;
 4ζ-methyl-de(4ζ-dimethylamino)pristinamycin I_H;
 4ζ-bromo-de(4ζ-dimethylamino)pristinamycin I_H;
 4ζ-iodo-de(4ζ-dimethylamino)pristinamycin I_H;
 4ζ-trifluoromethyl-de(4ζ-dimethylamino)pristinamycin I_H;

4ε-methoxy-de(4ζ-dimethylamino)pristinamycin I_H; and
4ζ-ethyl-de(4ζ-dimethylamino)pristinamycin I_H.

34. A compound according to claim 30, wherein said compound is at least one
of:

4ζ-isopropyl-de(4ζ-dimethylamino)pristinamycin I_E;
4ε-methoxy-de(4ζ-dimethylamino)pristinamycin I_A;
4ε-fluoro 4ζ-methyl-de(4ζ-dimethylamino)pristinamycin I_A; and
4ζ-amino-de(4ζ-dimethylamino)pristinamycin I_A.

35. A compound, wherein said compound is at least one of:

4-trifluoromethoxyphenylalanine;
3-methylaminophenylalanine;
3-methylthiophenylalanine;
3-fluoro-4-methylphenylalanine;
4-methylaminophenylpyruvic acid;
3-ethoxyphenylalanine;
4-allylaminophenylalanine;
4-diallylaminophenylalanine;
4-allylethylaminophenylalanine;
4-ethylpropylaminophenylalanine;
4-ethylisopropylaminophenylalanine;
4-ethylmethylcyclopropylaminophenylalanine;

4-(1-pyrrolidinyl)phenylalanine;
4-ethylthiomethylphenylalanine;
4-O-(2-chloroethyl)tyrosine;
3-dimethylaminophenylalanine; and
3-ethylaminophenylalanine.

36. A pharmaceutical composition, comprising at least one compound according to claim 30 and at least one pharmaceutically acceptable excipient.

37. A pharmaceutical composition, comprising at least one compound according to claim 31 and at least one pharmaceutically acceptable excipient.

38. A pharmaceutical composition, comprising at least one compound according to claim 32 and at least one pharmaceutically acceptable excipient.

39. A pharmaceutical composition, comprising at least one compound according to claim 33 and at least one pharmaceutically acceptable excipient.

40. A pharmaceutical composition, comprising at least one compound according to claim 34 and at least one pharmaceutically acceptable excipient.

41. The pharmaceutical composition according to claim 36, further comprising a Group A streptogramin.

42. The pharmaceutical composition according to claim 37, further comprising a Group A streptogramin.

43. The pharmaceutical composition according to claim 38, further comprising a Group A streptogramin.

44. The pharmaceutical composition according to claim 39, further comprising a Group A streptogramin.

45. The pharmaceutical composition according to claim 40, further comprising a Group A streptogramin.

46. A method for producing a compound of claim 30, comprising adding at least one compound selected from:

4-trifluoromethoxyphenylalanine;

3-methylaminophenylalanine;

3-methylthiophenylalanine;

3-fluoro-4-methylphenylalanine;

4-methylaminophenylpyruvic acid;

3-ethoxyphenylalanine;

4-allylaminophenylalanine;

4-diallylaminophenylalanine;

4-allylethylaminophenylalanine;
4-ethylpropylaminophenylalanine;
4-ethylisopropylaminophenylalanine;
4-ethylmethylcyclopropylaminophenylalanine;
4-(1-pyrrolidinyl)phenylalanine;
4-ethylthiomethylphenylalanine;
4-O-(2-chloroethyl)tyrosine;
3-dimethylaminophenylalanine; and
3-ethylaminophenylalanine;

to growth medium of at least one *Streptomyces* species or mutant thereof;
growing said species or mutant thereof under conditions permitting the synthesis
of said at least one compound; and
recovering said at least one compound.

47. The compound according to claim 30, wherein, for meta derivatives, B is
fluorine.

48. The compound according to claim 30, wherein, for meta derivatives, B is a
methyl or ethyl group.

49. The compound according to claim 30, wherein, for meta derivatives, B is a
trifluoromethyl group.

50. The compound according to claim 30, wherein, for para derivatives, at least one of R_1 and R_2 is a methyl, isopropyl, or tert-butyl group.

51. The compound according to claim 30, wherein, for para derivatives, at least one of R_1 and R_2 is a trifluoromethyl group.

52. The compound according to claim 30, wherein, for meta-para disubstituted derivatives, B is fluorine.

53. The compound according to claim 30, wherein, for meta-para disubstituted derivatives, B is a methyl or ethyl group.

54. The compound according to claim 30, wherein, for meta-para disubstituted derivatives, C is fluorine.

55. The compound according to claim 30, wherein, for meta-para disubstituted derivatives, C is a methyl amino or diakylamino group, wherein at least one of the alkyl groups of the diakylamino group is a methyl group, and B is not a bromine atom, a chlorine atom, or a substituted or unsubstituted allyl group.

56. The compound according to claim 30, wherein, for meta-para disubstituted derivatives, C is a trifluoromethyl group.

57. The compound according to claim 30, wherein, for para derivatives, at least one of R_1 and R_2 is a phenyl group.